The potent crosstalk of PRL with growth factor-initiated signals observed both in breast cancer cell lines (112, 142), and anti-estrogen resistant ER+ PDXs (128) has suggested that targeting PRL signaling in combination with these pathways may be an efficacious therapeutic strategy. Here, ESR1 is linked to breast carcinoma.